.jpg)
1 hour ago
3
Article content
HALIFAX, Nova Scotia, May 04, 2026 (GLOBE NEWSWIRE) — To mark World Ovarian Cancer Day, Ovarian Cancer Canada is announcing a $725,000 investment to fuel critical ovarian cancer research. Led by globally respected Canadian immunologist, Dr. Jeanette Boudreau, investment in this research project will prepare powerful natural killer (NK) cell immunotherapy to move into clinical trials, aiming to develop new and affordable treatment options for people facing ovarian cancer, one of the most fatal cancers affecting women.
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
Article content
“The vague symptoms of ovarian cancer mean women are often diagnosed at later stages, when their treatment options aren’t as effective long term,” said Tania Vrionis, CEO of Ovarian Cancer Canada, the only national health charity dedicated to eradicating ovarian cancer. “Dr. Jeanette Boudreau’s research has already shown that NK cells are associated with longer survival in patients with cancer. Now, thanks to the support of The River Philip Foundation and our community across Atlantic Canada, we can uncover how Canadians diagnosed with ovarian cancer can benefit from this new treatment. Our investment in Dr. Jeanette Boudreau’s work will tackle the challenges of ovarian cancer head-on and help expand Canada’s healthcare innovation ecosystem by enabling Atlantic Canada to become the centre for clinical trials-grade NK cell therapy production.”
Article content
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
This investment will not only enable development of a new class of immunotherapies for ovarian cancer, but it will also build an AI-powered tool that helps doctors and patients determine the best possible treatment plan.
Article content
Article content
“Ovarian cancer remains one of the most fatal and complex cancers, with historically insufficient research funding compared to cancers with higher rates of survival,” said Dr. Jeanette Boudreau, Departments of Microbiology & Immunology and Pathology, Dalhousie University, and lead researcher on the project. “After decades without meaningful change, we have an opportunity to not just give women facing ovarian cancer hope; we can give them hope that is achievable. This investment from Ovarian Cancer Canada will accelerate our development of immune-based, NK cell–driven therapies and help us build the infrastructure needed to make these powerful treatments more affordable and accessible to women.”
Article content
Ovarian cancer is a group of cancers that originate in the fallopian tubes and grow in the ovaries. Ovarian cancer is difficult to detect because of its vague symptoms including bloating, abdominal/pelvic pain, and difficulty eating. Approximately 3,000 Canadians will be diagnosed with ovarian cancer each year and it remains the most fatal women’s cancer, with a five-year survival rate of just 44%. After decades of underinvestment in ovarian cancer research and no change to survival rates, progress has been made – but it remains fragile. Ovarian Cancer Canada is focused on sustaining its investment in ovarian cancer research. To mark World Ovarian Cancer Day on May 8, Canadians are called on to continue investing in ovarian cancer research so we can advance women’s health, improve outcomes and save lives. Donate today at ovariancanada.org.
Article content
About Ovarian Cancer Canada
Ovarian Cancer Canada is the only national charity dedicated to overcoming ovarian cancer by advancing research, advocating for better care, and supporting those affected by the disease. The organization is driving progress toward more effective treatments and improved outcomes for patients across the country.
Article content
Media Contacts:
Jack Glassco
Account Executive, Paradigm Public Relations
[email protected]
Article content
Namrata Peri
Director, Marketing and Communications, Ovarian Cancer Canada
[email protected]
Article content
Article content
Article content
Article content
Article content
Article content
English (US)